Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hormone clues sought in rare nerve disease

NCT ID NCT07266051

Knowledge-focused Sponsor: Xiamen Hospital of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will measure sex hormone levels in 4000 people with NMOSD, a rare autoimmune disease affecting the nerves. Researchers want to see if hormone changes are linked to the disease. Participants will give blood samples for hormone testing. The study does not test any new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal how sex hormones influence NMOSD, pointing toward new ways to manage the disease.
What could go wrong
This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to any new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 4,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population of NMOSD patients in Southern China

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Inclusion Criteria for the NMOSD Patient Group * Aged 18 years or older, regardless of sex * Fulfilled the diagnostic criteria for Neuromyelitis Optica Spectrum Disorders as defined by the 2021 Chinese guidelines for the diagnosis and management of NMOSD * Seropositive for AQP4-IgG * Provided informed consent by the participant or their legal guardian Inclusion Criteria for the Healthy Control Group * Aged 18 years or older, regardless of sex * Gender- and age-matched healthy individuals * Provided informed consent by the participant or their legal guardian Exclusion Criteria * Diagnosis of other serious systemic diseases (e.g., malignancy) * Presence of severe psychiatric disorders that would preclude compliance with study procedures and/or follow-up assessments * History of infectious pathologies of the central nervous system * Those with severe liver and kidney function impairment or dysfunction of other vital organs * Patients with other conditions that do not allow participation in clinical research * Patients allergic to gadolinium-DPTA * Patients with other conditions that do not allow participation in clinical research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMOSD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NMOSD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Xiamen university

    Xiamen, Fujian, 361000, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, 361000, China

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, Fujian, 361000, China

  • Zhongshan Hospital (Xiamen), Fudan University

    Xiamen, Fujian, 361000, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.